Clinical trials: Thalidomide
HIV Infections
A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection
PRIMARY: To evaluate the safety, tolerability, and pharmacokinetics of daily oral thalidomide. SECONDARY: To examine the effect of thalidomide on antiviral activity and tumor necrosis factor-alpha (TNF-alpha) production, and the…
- Trial name
- NCT00000812
- Testing
- Thalidomide
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Inflammatory Bowel Diseases
Thalidomide Therapy for VEOIBD
This is a single center, observational study to investigate the clinical outcomes of thalidomide treatment for very early onset inflammatory bowel disease
- Trial name
- NCT06382519
- Testing
- Thalidomide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Children's Hospital of Fudan University
Idiopathic Pulmonary Fibrosis, Cough
Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide
Idiopathic Pulmonary Fibrosis (IPF) is a rapidly progressive lung disorder that is often associated with a chronic, intractable cough.
- Trial name
- NCT00600028
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Johns Hopkins University
Scleroderma, Systemic
Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
Progressive systemic sclerosis (SSc) is an immune-based disease that causes abnormal connective tissue growth of the skin and internal organs. At this point, there are no effective therapies for treating SSc.
- Trial name
- NCT00418132
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Multiple Myeloma
VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)
Thalidomide-Dexamethasone (TD) is a standard induction therapy for Multiple Myeloma (MM). The present study is designed to compare TD with VELCADE-Thalidomide-Dexamethasone (VTD) as induction therapy in preparation for, and as…
- Trial name
- NCT01134484
- Testing
- Velcade, Thalidomide, Dexamethasone
- Where
- Italy
- Volunteers
- 480 people
- Sponsor
- Michele Cavo
Systemic Lupus Erythematosus
Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76
This pooled analysis will assess data from the Phase 3 belimumab registration studies BLISS-52 (aka BEL110752) and BLISS-76 (aka BEL110751). The analysis was pre-planned and agreed prior to the unblinding of either study.
- Trial name
- NCT01914770
- Testing
- Belimumab 1 mg/kg, Belimumab 10 mg/kg
- Volunteers
- 1,016 people
- Sponsor
- GlaxoSmithKline
Dermatologic, Other
Expanded Access for CC-2001
This is an expanded access program (EAP) for eligible participants designed to provide access to CC-2001.
- Trial name
- NCT03723083
- Testing
- CC-2001
- Where
- United States
- Sponsor
- Celgene
Lymphoma, Multiple Myeloma
Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer
In cancer, the incidence of venous thromboembolism (VTE) is particularly high in patients with myeloma, especially when it is de novo and treated with thalidomide, lenalidomide or erythropoietin.
- Trial name
- METRO B (NCT02260414)
- Testing
- Tinzaparin, Blood sample
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Multiple Myeloma, Daratumumab
Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.
Daratumumab is a human first-in-class monoclonal antibody that targets a cluster of differentiation (CD) 38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells, showing significant activity in…
- Conditions
- Multiple Myeloma, Daratumumab, Autologous Stem Cell Transplantation, Leukapheresis
- Trial name
- DILEMMA (NCT05835726)
- Testing
- Daratumumab
- Where
- Italy
- Volunteers
- 188 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma
Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence
This single-centered phase II clinical study is to obtain preliminary information on 1-year recurrence-free survival rate, recurrence-free survival and safety profile of thalidomide in combination with tegafur-uracil in…
- Conditions
- Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Adverse Reaction to Drug, Vascular Endothelial Growth Factor Overexpression
- Trial name
- NCT02447679
- Testing
- thalidomine, tegafur-uracil
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
Multiple Myeloma de Novo Treatment
Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.
The aim of the study was to evaluate efficacy and tolerability of Thalidomide in first-line treatment of multiple myeloma as induction treatment in young patients, with Dexamethasone before autotransplant, and in elderly patients…
- Trial name
- MAG 2002 (NCT01070862)
- Testing
- Thalidomide, Dexamethasone, Vincristin , Adriamycin, Dexamethasone = VAD, Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal)
- Where
- 3 sites in France
- Sponsor
- University Hospital, Caen
Prostate Cancer
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate
RATIONALE: Drugs used in chemotherapy, such as docetaxel and estramustine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00083005
- Testing
- docetaxel, estramustine phosphate sodium, thalidomide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatocellular Carcinoma
UFUR Plus Thalidomide for Advanced Hepatocellular Carcinoma
We hypothesize that combination of tegafur/uracil(UFUR) and thalidomide, both of which have been shown to be active in some HCC patients,may be a highly useful regimen for the treatment of advanced HCC.
- Trial name
- NCT00519688
- Testing
- Thalidomide, Tegafur/Uracil
- Where
- Taiwan
- Volunteers
- 44 people
- Sponsor
- National Taiwan University Hospital
Myeloma
Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
The goal of this clinical research study is to learn if adding low dose Thalidomide (thalidomide) to Revlimid (lenalidomide) maintenance therapy will help control MM after an autologous stem cell transplant.
- Trial name
- NCT01927718
- Testing
- Thalidomide, Lenalidomide, Questionnaires
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining thalidomide with chemotherapy may kill more tumor cells and be an effective treatment for stage IIIB or stage IV non-small cell…
- Trial name
- NCT00025285
- Testing
- carboplatin, irinotecan hydrochloride, thalidomide
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- Wake Forest University Health Sciences
Multiple Myeloma
DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation
The purpose of this study is to find out if transplant with a new regimen of chemotherapy called DT PACE-Melphalan is better than transplant with Melphalan alone.
- Trial name
- NCT00083915
- Testing
- Cisplatin, Cyclophosphamide, Adriamycin
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- University of Arkansas
Relapse/Refratory Peripheral T Cell Lymphoma
Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma
The purpose of this study is to investigate efficacy and safety of Chidamide Combined With Cyclophosphamide,Prednisone,Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma :a Phase…
- Trial name
- NCT02879526
- Testing
- C-CPT
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma
Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
This phase II trial is studying how well thalidomide works in treating patients with carcinosarcoma of the uterus that has come back or that does not go to remission (decrease or disappear but may still be in the body) despite…
- Trial name
- NCT00025506
- Testing
- Laboratory Biomarker Analysis, Thalidomide
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Hepatitis C
Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance
INDICATION: Patients with chronic hepatitis C, genotype 1 and non-responders to standard treatment for hepatitis C. OBJECTIVES: 1.
- Trial name
- TRITAL (NCT00856804)
- Testing
- thalidomide
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Valme University Hospital
Gastrointestinal Bleeding of Unknown Origin, Gastrointestinal Vascular Malformation
Retreatment and Its Efficiency of Thalidomide for Vascular Malformation Patients With Failure of First Course Treatment
Background: Repeated episodes of bleeding from gastrointestinal vascular malformations refractory to endoscopic or surgical therapy often pose a major therapeutic challenge.
- Conditions
- Gastrointestinal Bleeding of Unknown Origin, Gastrointestinal Vascular Malformation, Thalidomide Efficiency
- Trial name
- NCT02301949
- Testing
- Thalidomide
- Where
- China
- Sponsor
- Zhizheng Ge